73m2, p=0.001 in ETV group, respectively). Conclusion: TDF and ETV produce similar treatment response and clinical outcomes in CHB patients with severe acute exacerbation. Disclosures: The following people have nothing to disclose: Chao-Hung Hung, Chien-Hung Chen, Sheng-Nan Lu, Tsung-Hui Hu, JIng-Houng Wang, selleck Chuan-Mo Lee Background/aim To investigate the efficacy of tenofovir (TDF) rescue therapy for patients with drug-resistant chronic hepatitis B in Korea. Methods In this retrospective cohort study, 76 patients received TDF with or without
nucleoside analogues more than 12 months. Suboptimal response was defined as serum HBV-DNA level above 60 IU/mL during prior rescue therapy. Multi-drug resistance was defined as two or more drug resistance-related mutations were confirmed by mutation detection assay. The relationship between baseline characteristics and virological response (HBV DNA < 20 IU/mL) at month 12 were evaluated using logistic regression analysis. Results Fifty-five (72%) of patients were suboptimal responders to prior rescue therapy. Twenty-six (34%) of the subjects had multi-drug resistance and VX-770 solubility dmso 21 had adeforvir resistant mutation. Baseline HBV DNA levels was 4.4 (1.8-7.9) log10 IU/mL and 62 (81%) of patients were HBeAg positive. Forty-two (55%) of the subjects received
nucleoside analogues with TDF and 26 patients treated with TDF and entecavir. Viological response was achieved in 58 (76%) patients at 12 months. Combination with nucleoside analogues (P = 0.104), prior rescue therapy (P = 0.242), multi-drug resistance (P = 0.632), adefovir resistance (P = 0.987), mutation on rtN236 (P = 0.987), HBeAg positive (P = 0.186), and underlying cirrhosis Fenbendazole (P = 0.139) were not related, however gender (P = 0.047), and baseline HBV-DNA
level (P = 0.014) were associated with virological response by univariate analysis. In multivariate analysis, gender (male, OR = 0.08; 95% CI = 0.01-0.81, P = 0.032), baseline HBV-DNA level (< 4.3 log IU/mL, OR = 6.05; 95% CI = 1.47-24.9, P = 0.013), and combination with nucleoside analogues (yes, OR = 0.23; 95% CI = 0.05-0.97, P = 0.046) were significantly correlated with virological response at month 12. Conclusions Adefovir resistant mutation was not related with virological response of TDF rescue therapy and combination with nucleo-side analogues was a significant factor in patients with drug-resistant chronic hepatitis B. Disclosures: The following people have nothing to disclose: Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon Despite the excellent safety records of tenofovir disoproxil fumarate (TDF), a few cases of Fanconi syndrome have been reported among human immunodeficiency virus (HIV) positive patients, and recently two cases of TDF-associated Fanconi syndrome have been reported in chronic hepatitis B (CHB) patients from Australia.